EAST WINDSOR, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Novitium Pharma LLC today announced that it has received U.S. Food and Drug Administration approval on its Abbreviated New Drug Application (“ANDA”) for Prazosin Hydrochloride Capsules USP 1 mg, 2 mg, and 5 mg, and has immediately initiated commercialization activities. Prazosin Hydrochloride USP is a therapeutic equivalent to the reference listed drug Minipress® of Pfizer Inc.  For the 12 months ended June 2018, total U.S. sales of Prazosin Capsules USP 1 mg, 2 mg, and 5 mg was approximately $65 million according to IQVIA.

About Novitium Pharma

Novitium is a U.S. based pharmaceutical company that specializes in development, manufacturing, and distribution of niche generic pharmaceutical products.  The company, founded in 2016, has since established a growing commercial product portfolio and developed a pipeline of over 20 ANDAs filed with the FDA, spanning a diverse range of dosage forms and therapeutic categories.  Novitium continues to invest in producing affordable, high-quality medication to fulfill the needs of pharmacists, patients, and communities alike.

For more information about Novitium Pharma please visit www.novitiumpharma.com.

Contact:
Chad Gassert
Novitium Pharma LLC
chad.gassert@novitiumpharma.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.